Evidence map›Paper›PMID 31346257›Full record

ReviewNature reviews. Cardiology2020

Drug-eluting coronary stents: insights from preclinical and pathology studies.

Sho Torii, Hiroyuki Jinnouchi, Atsushi Sakamoto, Matthew Kutyna, Anne Cornelissen, Salome Kuntz, Liang Guo, Hiroyoshi Mori, Emanuel Harari, Ka Hyun Paek and 7 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

105 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Durable-polymer versus biodegradable-polymer drug-eluting stents in acute coronary syndromes: three-year outcomes of the HOST REDUCE POLYTECH RCT Trial.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2024
    Trial
  7. Trial
  8. Trial
  9. Durable polymer versus biodegradable polymer drug-eluting stents in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention: a post hoc analysis of the HOST-REDUCE-POLYTECH-ACS trial.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2022
    Trial
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Towards Neoatherosclerosis: A Porcine Model for Enhanced Device Testing.Journal of cardiovascular translational research · 2026
    Article
  20. Review

45 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Sho ToriiCVPath Institute, Gaithersburg, MD, USA.
Hiroyuki JinnouchiCVPath Institute, Gaithersburg, MD, USA.
Atsushi SakamotoCVPath Institute, Gaithersburg, MD, USA.
Matthew KutynaCVPath Institute, Gaithersburg, MD, USA.
Anne CornelissenCVPath Institute, Gaithersburg, MD, USA.ORCID http://orcid.org/0000-0002-5452-4657
Salome KuntzCVPath Institute, Gaithersburg, MD, USA.
Liang GuoCVPath Institute, Gaithersburg, MD, USA.
Hiroyoshi MoriCVPath Institute, Gaithersburg, MD, USA.
Emanuel HarariCVPath Institute, Gaithersburg, MD, USA.ORCID http://orcid.org/0000-0003-4454-5857
Ka Hyun PaekCVPath Institute, Gaithersburg, MD, USA.
Raquel FernandezCVPath Institute, Gaithersburg, MD, USA.
Diljon ChahalSchool of Medicine, University of Maryland, Baltimore, MD, USA.
Maria E RomeroCVPath Institute, Gaithersburg, MD, USA.
Frank D KolodgieCVPath Institute, Gaithersburg, MD, USA.
Anuj GuptaSchool of Medicine, University of Maryland, Baltimore, MD, USA.
Renu VirmaniCVPath Institute, Gaithersburg, MD, USA.
Aloke V FinnCVPath Institute, Gaithersburg, MD, USA. afinn@cvpath.org.ORCID http://orcid.org/0000-0003-0359-0184

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Implantation of drug-eluting stents (DES) is the dominant treatment strategy for patients with symptomatic coronary artery disease. However, the first-generation DES had substantial drawbacks, including delayed healing, local hypersensitivity reactions and neoatherosclerosis, which all led to a steady increase in major adverse cardiovascular events over time. Subsequently, newer-generation DES were introduced with thinner struts, different scaffold designs (to improve deliverability while maintaining radial strength), different durable and biodegradable polymers - and in some cases no polymer (to improve vascular biocompatibility) - and new antiproliferative drug types and doses. Currently, >30 different DES are commercially available in Europe, with fewer available in the USA but with many new entrants coming onto the US market in the next few years. Never before have cardiologists been faced with so many choices of stent, each with its own unique design. In this Review, we detail preclinical and pathology studies for each stent design, examining thromboresistance, speed of neointimal coverage and completeness of healing, including endothelialization. We conclude by discussing how these design characteristics might affect the potential for shortening the minimum duration of dual antiplatelet therapy needed after coronary intervention.

Indexed as

Drug-Eluting StentsWound HealingAnimalsCell ProliferationCoronary Artery DiseaseCoronary VesselsHumansNeointimaPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsProsthesis DesignRisk FactorsTreatment OutcomePlatelet Aggregation Inhibitors

Identifiers

PMID31346257

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.